Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573816 | 0.95 | NTRK1 (0.46) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL574253 | 0.94 | NTRK1 (0.45) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL574391 | 0.93 | IRAK4 (0.48) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL573164 | 0.93 | NTRK1 (0.44) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL574065 | 0.91 | NTRK1 (0.54) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL572717 | 0.90 | NTRK1 (0.43) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL574121 | 0.89 | KDR (0.42) | IRAK4KDRRIPK1RIPK3CTSC | |
| SCHEMBL574608 | 0.88 | NTRK1 (0.46) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL573890 | 0.88 | NTRK1 (0.43) | IRAK4NTRK1KDRRETEPHB2 | |
| SCHEMBL574518 | 0.87 | NTRK1 (0.46) | IRAK4NTRK1KDRRETEPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | IRAK4 1542/4885NTRK1 1105/4885KDR 2434/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | IRAK4 501/4885NTRK1 211/4885KDR 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.